
Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(145 produits)
- Bcr-Abl(102 produits)
- EGFR(572 produits)
- FAK(72 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(170 produits)
- JAK(245 produits)
- PDGFR(126 produits)
- RAAS(86 produits)
- Src(78 produits)
- Syk(38 produits)
- Thrombine(47 produits)
- VDA(2 produits)
- VEGFR(268 produits)
Affichez 6 plus de sous-catégories
1414 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
ALK-IN-22
CAS :<p>ALK-IN-22 suppresses ALK and mutants (IC50: 2.3-3.7 nM), hinders phosphorylation, and induces apoptosis in tumor studies.</p>Formule :C24H24ClN7O2Couleur et forme :SolidMasse moléculaire :477.95RIPK2-IN-1
CAS :<p>RIPK2-IN-1 (compound 18f) is a potent inhibitor of RIPK2 (IC50: 51 nM) and also inhibits ALK2 (IC50: 5 nM).</p>Formule :C23H27N5O3SCouleur et forme :SolidMasse moléculaire :453.56EGFR-IN-59
CAS :<p>EGFR-IN-59: EGFR inhibitor, IC50 = 190 nM, induces apoptosis, cytotoxic to A549 cells (IC50 = 8.62 μM) and WI38 cells (IC50 = 52.6 μM). Use: Various cancers.</p>Formule :C27H23N5O4SCouleur et forme :SolidMasse moléculaire :513.57RET-IN-19
CAS :<p>RET-IN-19, a potent RET inhibitor, anticancer: IC50 6.8 nM (RET-wt), 13.51 nM (RET V804M); for NSCLC research.</p>Formule :C28H28N6O4SCouleur et forme :SolidMasse moléculaire :544.62TyK2-IN-2
CAS :<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Formule :C16H18N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :310.35VA5 TG2 inhibitor
CAS :<p>VA5 inhibits transamidase and GTP-binding by locking protein in an open state, disabling GTPase.</p>Formule :C31H34N4O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :590.62ARQ 069
CAS :<p>ARQ 069 inhibits FGFR2 phosphorylation concentration-dependently (IC50: 9.7 µM), without affecting β-actin. Preferentially binds inactive FGFR1/2.</p>Formule :C18H15N3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :273.33JTV-519 free base
CAS :<p>JTV-519 free base (K201 free base), recognized for its antiarrhythmic and cardioprotective properties, functions as a Ca2+-dependent blocker of sarcoplasmic</p>Formule :C25H32N2O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :424.6EGFR-IN-46
CAS :<p>EGFR-IN-46: Potent EGFR/FAK inhibitor (IC50: 20.17 & 14.25 nM), curbs cancer cell growth, triggers apoptosis.</p>Formule :C27H32F3N3O3Couleur et forme :SolidMasse moléculaire :503.56Y 11
CAS :<p>focal adhesion kinase (FAK) inhibitor</p>Formule :C8H17BrN4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :265.15FLT3-IN-6
CAS :<p>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.</p>Formule :C23H25N5O3Couleur et forme :SolidMasse moléculaire :419.48KBP-7018
CAS :<p>KBP-7018: potent tyrosine kinase inhibitor targeting c-KIT, RET, PDGFR with IC50s of 10, 7.6, 25nM.</p>Formule :C31H30N4O5Couleur et forme :SolidMasse moléculaire :538.59CGI560
CAS :<p>CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.</p>Formule :C29H27N5OCouleur et forme :SolidMasse moléculaire :461.56MBM-55S
CAS :<p>MBM-55S, a Nek2 inhibitor with 1 nM IC50, induces cell cycle arrest and apoptosis, suppressing tumor growth.</p>Formule :C36H39FN6O10Degré de pureté :99.37% - 99.89%Couleur et forme :SolidMasse moléculaire :734.73BMS-243117
CAS :<p>BMS-243117: Selective LCK inhibitor, IC50=1.1µM, inhibits T cell growth, promising for immunosuppression, arthritis, asthma treatment.</p>Formule :C20H21ClN4O2SCouleur et forme :SolidMasse moléculaire :416.92BTK-IN-9
CAS :<p>BTK-IN-9 reversibly inhibits BTK, disrupts mitochondria, boosts ROS, and triggers apoptosis in Z138 cells, impeding condyloma cell growth.</p>Formule :C25H19N7O4Couleur et forme :SolidMasse moléculaire :481.46JAK-IN-14
CAS :<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Formule :C19H15FN4ODegré de pureté :98.27%Couleur et forme :SolidMasse moléculaire :334.35JAK-IN-18
CAS :<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Formule :C27H28F2N6O3Couleur et forme :SolidMasse moléculaire :522.55HZ-A-005
CAS :<p>HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.</p>Formule :C25H23ClN6O2Couleur et forme :SolidMasse moléculaire :474.94ALK-IN-21
CAS :<p>ALK-IN-21 (B10) inhibits ALK WT (IC50: 4.59nM), L1196M (2.07nM), G1202R (5.95nM); curbs Karpas299, H2228 cell growth; for ALCL research.</p>Formule :C35H45ClN6O6S4Couleur et forme :SolidMasse moléculaire :809.48Tyrphostin 51
CAS :<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Formule :C13H8N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :268.23GDC-0834 S-enantiomer
CAS :<p>GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).</p>Formule :C33H36N6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :596.74Atopaxar
CAS :<p>Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Formule :C29H38FN3O5Degré de pureté :97.07% - 98.07%Couleur et forme :SolidMasse moléculaire :527.63JNJ28871063 hydrochloride
CAS :<p>ErbB receptor family inhibitor</p>Formule :C24H28Cl2N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :519.42AAE871
CAS :<p>AAE871 is a type I FLT3 inhibitor.</p>Formule :C24H34N8O2SCouleur et forme :SolidMasse moléculaire :498.64pan-HER-IN-1
CAS :<p>Compound C5: Irreversible, oral pan-HER inhibitor with low IC50s for EGFR/HERs; induces apoptosis and has antitumor effects.</p>Formule :C19H14BrN5OCouleur et forme :SolidMasse moléculaire :408.25Nuvenzepine
CAS :<p>Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment.</p>Formule :C19H20N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :336.39HS-438
CAS :<p>HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.</p>Formule :C17H17N3O3SCouleur et forme :SolidMasse moléculaire :343.4EL-102
CAS :<p>EL-102 is a HIF1α inhibitor with anticancer activity that inhibits microtubule protein polymerization and can be used to study prostate cancer.</p>Formule :C19H16N2O3S2Degré de pureté :99.34%Couleur et forme :SolidMasse moléculaire :384.47Sch 13835
CAS :<p>Sch 13835 is an inhibitor of platelet derived growth factor.</p>Formule :C15H10ClNO4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :335.76EGFR-IN-64
CAS :<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Formule :C20H21N3O3Couleur et forme :SolidMasse moléculaire :351.4Atopaxar Hydrobromide
CAS :<p>Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Formule :C29H39BrFN3O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :608.54TG 100801 Hydrochloride
CAS :<p>TG 100801: prodrug for macular degeneration. TG 100572: inhibits kinases (VEGFRs, FGFRs, PDGFRβ, Src family), with varying IC50s.</p>Formule :C33H31Cl2N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :616.54MAX-40279 hemifumarate
CAS :<p>MAX-40279 hemifumarate inhibits FLT3 and FGFR kinases, showing promise for AML treatment.</p>Formule :C48H50F2N12O6S2Couleur et forme :SolidMasse moléculaire :993.12BCR-ABL-IN-2
CAS :<p>BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).</p>Formule :C24H25Cl2N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :502.39BLK-IN-2
CAS :<p>BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂,具有5.9 nM的IC50值。该化合物亦能抑制BTK,其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。</p>Formule :C39H41N9O3Couleur et forme :SolidMasse moléculaire :683.8TM-233
CAS :<p>TM-233 is an inhibitor of both JAK/STAT and proteasome activities that acts by inducing cell death in myeloma cells.</p>Formule :C25H20O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :384.42EGFR-IN-56
CAS :<p>EGFR-IN-56 (13a) inhibits EGFR, EGFRT790M (IC50: 541.7nM), EGFRT790M/L858R (IC50: 132.1nM), blocks G2/M phase, and triggers apoptosis.</p>Formule :C23H22N4O3SCouleur et forme :SolidMasse moléculaire :434.51JAK3-IN-12
CAS :<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Formule :C19H19N5O4SCouleur et forme :SolidMasse moléculaire :413.45Ilorasertib hydrochloride
CAS :<p>Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s:</p>Formule :C25H22ClFN6O2SDegré de pureté :98.45%Couleur et forme :SolidMasse moléculaire :525HSP90-IN-13
CAS :<p>HSP90-IN-13 (5k): potent HSP90 inhibitor, IC50 25.07 nM, targets EGFR/VEGFR-2/Topo-2, blocks MCF-7 G2/M cycle, induces apoptosis.</p>Formule :C26H21N5O3SCouleur et forme :SolidMasse moléculaire :483.54M1002
CAS :<p>M1002, a HIF-2 agonist, boosts HIF-2alpha/ARNT activation and alters HIF-281alpha PAS-B, working with PHD inhibitors.</p>Formule :C15H8F6N2O2SDegré de pureté :99.95%Couleur et forme :SolidMasse moléculaire :394.29Tyk2-IN-5
CAS :<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Formule :C21H19FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :434.43JBJ-04-125-02
CAS :<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Formule :C29H26FN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :543.61VEGFR-2-IN-19
CAS :<p>VEGFR-2-IN-19 (15b) effectively inhibits VEGFR2, induces apoptosis, and increases oxidative stress, showing potential as an anticancer drug.</p>Formule :C21H19N3O2Couleur et forme :SolidMasse moléculaire :345.39BPTQ
CAS :<p>BPTQ: DNA intercalator, halts cancer cell growth by blocking S/G2/M phases.</p>Formule :C17H16N4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :308.4FAK-IN-8
CAS :<p>FAK-IN-8 (compound 5h), a FAK inhibitor with an IC50 of 5.32 μM, exhibits potent anti-proliferative activity, making it suitable for use in cancer research [1].</p>Formule :C15H9Cl2N3O2SCouleur et forme :SolidMasse moléculaire :366.22ULK1-IN-2
CAS :<p>ULK1-IN-2, a potent anticancer agent, inhibits ULK1, induces apoptosis, blocks autophagy, and shows high cytotoxicity with an IC50 of 1.94 μM in A549 cells.</p>Formule :C19H16BrFN4O6Degré de pureté :99.25% - 99.25%Couleur et forme :SolidMasse moléculaire :495.26R916562
CAS :<p>R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.</p>Formule :C26H30ClN9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :536.09AZM475271
CAS :<p>AZM475271 is a potent and selective inhibitor of Src kinase(IC50 : 5 nM)</p>Formule :C23H27ClN4O3Degré de pureté :99.78%Couleur et forme :SolidMasse moléculaire :442.94(R)-Afatinib
CAS :<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Formule :C24H25ClFN5O3Couleur et forme :SolidMasse moléculaire :485.94MAX-40279 hemiadipate
CAS :<p>MAX-40279 hemiadipate: Potent FLT3/FGFR inhibitor; potential in AML treatment. (Patent WO2021180032A1)</p>Formule :C50H56F2N12O6S2Couleur et forme :SolidMasse moléculaire :1023.19TX-1123
CAS :<p>TX-1123: PTK/COX inhibitor, Src/eEF2-K/PKA/EGFR-K/PKC targeted, IC50 of 1.16μM(COX2), 15.7μM(COX1), low mitochondrial toxicity.</p>Formule :C20H24O3Couleur et forme :SolidMasse moléculaire :312.4NSC-689857
CAS :<p>NSC-689857 is an inhibitor that acts in the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro.</p>Formule :C25H29NO4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.5EGFR/HER2/CDK9-IN-2
CAS :<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Formule :C23H20N4O5S2Couleur et forme :SolidMasse moléculaire :496.56GDC-0834 Racemate
CAS :<p>GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitor</p>Formule :C33H36N6O3SCouleur et forme :SolidMasse moléculaire :596.74OD36
CAS :<p>OD36: Potent RIPK2 inhibitor, IC50=5.3 nM; hinders ALK2 signaling and osteogenesis, KD=37 nM; targets ALK2 ATP pocket.</p>Formule :C16H15ClN4O2Degré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :330.77GW768505A free base
CAS :<p>GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2 (pIC50: 7.81 for VEGFR2) with anti-angiogenic activity.</p>Formule :C27H19F4N5O3Couleur et forme :SolidMasse moléculaire :537.47JAK3/BTK-IN-5
CAS :<p>JAK3/BTK-IN-5 is a potent dual inhibitor targeting JAK3 and BTK with synergistic effects, valuable for related autoimmune disease research.</p>Formule :C19H22ClN7O2Couleur et forme :SolidMasse moléculaire :415.88T-1840383
CAS :<p>T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.</p>Formule :C30H25ClFN5O4Couleur et forme :SolidMasse moléculaire :574PD 166326
CAS :<p>PD166326, a pyridopyrimidine inhibitor, targets Src & Abl tyrosine kinases (IC50: 6 nM & 8 nM) and exhibits antileukemic effects.</p>Formule :C21H16Cl2N4O2Couleur et forme :SolidMasse moléculaire :427.28TG 100572
CAS :<p>TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2</p>Formule :C26H26ClN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :475.97LBW242
CAS :<p>LBW242: oral 3-mer Smac mimetic, IAP inhibitor, targets multiple myeloma, enhances TRAIL/chemo death in ovarian cancer, active on mutant FLT3 cells.</p>Formule :C27H42N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :454.65Syk-IN-1
CAS :<p>Syk-IN-11 is a selective Syk inhibitor.</p>Formule :C18H22N8OCouleur et forme :SolidMasse moléculaire :366.42SB-633825
CAS :<p>SB-633825 can inhibit cancer cell growth and angiogenesis.</p>Formule :C28H25N3O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :483.58OICR-0547
CAS :<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Formule :C28H29F3N4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :542.55ALK2-IN-5
CAS :<p>ALK2-IN-5, a pyrazolopyrimidine compound, serves as an inhibitor of ALK2 and FGFR, targeting disorders linked with their activity, including cancer [1].</p>Formule :C24H32N8O2Couleur et forme :SolidMasse moléculaire :464.56Depatuxizumab mafodotin
CAS :<p>Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].</p>Couleur et forme :LiquidVEGFR-2-IN-20
CAS :<p>VEGFR-2-IN-20 (Compound 7) is a highly effective VEGFR inhibitor with significant potential for cancer research [1].</p>Formule :C20H20N4O3SCouleur et forme :SolidMasse moléculaire :396.46PF-00337210
CAS :<p>PF-00337210, an oral VEGFR2 inhibitor, may hinder endothelial and tumor cell growth, reducing angiogenesis and potentially causing cancer cell death.</p>Formule :C26H27N3O5Couleur et forme :SolidMasse moléculaire :461.51EGFR-IN-89
CAS :<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Formule :C26H31FN8O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :538.64Gefitinib N-oxide
CAS :<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Formule :C22H24ClFN4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :462.9Ibrutinib-MPEA
CAS :<p>Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.</p>Formule :C32H39N9O2Couleur et forme :SolidMasse moléculaire :581.71BIIB-057
CAS :<p>BIIB-057 is a selective Syk inhibitor.</p>Formule :C19H23N9ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :393.45Sitravatinib malate
CAS :<p>Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5</p>Formule :C37H35F2N5O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :763.76VEGFR-2-IN-27
CAS :<p>VEGFR-2-IN-27 (compound 7a) is a potent inhibitor of VEGFR-2 (IC50: 14.8 nM) and can be used in anticancer studies.</p>Formule :C25H21FN4O4Couleur et forme :SolidMasse moléculaire :460.46CP-547632 hydrochloride
CAS :<p>CP-547632 hydrochloride: oral VEGFR-2/FGF inhibitor (IC50: 11/9 nM), well-tolerated, antitumor.</p>Formule :C20H25BrClF2N5O3SCouleur et forme :SolidMasse moléculaire :568.86FLT3/ITD-IN-3
CAS :<p>FLT3/ITD-IN-3 (Compound 19) is a potent FLT3-ITD inhibitor with IC50 values: FLT3D835Y (0.3 nM), FLT3 (0.4 nM), inhibits AML cell proliferation.</p>Formule :C22H26ClN7O2Couleur et forme :SolidMasse moléculaire :455.94WY-135
CAS :<p>WY-135 is a dual inhibitor of ALK and ROS1 (IC50 of 1.4 nM and 1.1 nM, respectively).</p>Formule :C28H34ClN9O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :612.15FIIN-4
CAS :<p>FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.</p>Formule :C35H38N8O4Degré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :634.73EP009
CAS :<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Formule :C14H24O2Couleur et forme :SolidMasse moléculaire :224.34AG1433
CAS :<p>AG1433: inhibits tyrosine kinases, PEP carboxylase, PDGFR-β, Flk-1, and angiogenesis.</p>Formule :C16H15ClN2O2Couleur et forme :SolidMasse moléculaire :302.76EGFR-IN-51
CAS :<p>EGFR-IN-51 effectively inhibits EGFR and mutations with IC50s of 0.493-461.63 μM; it induces apoptosis in cancer cells.</p>Formule :C21H15N3O2SCouleur et forme :SolidMasse moléculaire :373.43CHMFL-ABL/KIT-155
CAS :<p>CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM).</p>Formule :C33H38F3N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :609.68Tyk2-IN-7
CAS :<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Formule :C18H15D3N6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :401.46MS-1020
CAS :<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Formule :C21H18N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :346.38Cenisertib
CAS :<p>Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well</p>Formule :C24H30FN7OCouleur et forme :SolidMasse moléculaire :451.541,2,3,4,5,6-Hexabromocyclohexane
CAS :<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Formule :C6H6Br6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :557.54MS 39
CAS :<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Formule :C55H71ClFN9O7SCouleur et forme :SolidMasse moléculaire :1056.72PF-06651481-00
CAS :<p>PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.</p>Formule :C26H29Cl2N5O3Degré de pureté :97.01%Couleur et forme :SolidMasse moléculaire :530.45INCB16562
CAS :<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Formule :C19H11Cl2N5Couleur et forme :SolidMasse moléculaire :380.23Jaspamycin
CAS :<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Formule :C12H12N4O5Couleur et forme :SolidMasse moléculaire :292.25FLT3-IN-12
CAS :<p>FLT3-IN-12: potent, selective oral FLT3 inhibitor; FLT3-WT IC50: 1.48 nM, FLT3-D835Y: 2.87 nM; >1000x selective over c-KIT; anti-AML, IC50: 0.75 nM MV4-11.</p>Formule :C21H23F3N6OCouleur et forme :SolidMasse moléculaire :432.44JAK3-IN-9
CAS :<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Formule :C17H23N5O4SCouleur et forme :SolidMasse moléculaire :393.46ALK5-IN-29
CAS :<p>ALK5-IN-29: selective ALK inhibitor, IC50 ≤ 10 nM, curbs tumor growth, aids in cancer research.</p>Formule :C24H25FN8Couleur et forme :SolidMasse moléculaire :444.51NVP-AAD777
CAS :<p>NVP-AAD777 is a specific VEGFR-2 inhibitor.</p>Formule :C22H14F6N4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.36VEGFR-2/BRAF-IN-1
<p>VEGFR-2/BRAF-IN-1 inhibits VEGFR-2, BRAF V600E & BRAF WT with IC50 of 49, 63 and 5 nM, triggers apoptosis, and halts G1/S cell cycle.</p>Formule :C26H20Cl2F3N5O3S2Couleur et forme :SolidMasse moléculaire :642.5XST-14
CAS :<p>XST-14 is a ULK1 inhibitor.XST-14 induces apoptosis and inhibits the growth of HCC cells.</p>Formule :C16H21NO4Degré de pureté :99.84% - 99.84%Couleur et forme :SolidMasse moléculaire :291.34GZD856
CAS :<p>GZD856 is an orally bioavailable PDGFRα/β inhibitor (IC50s: 68.6 and 136.6 nM) with anti-lung cancer activities.</p>Formule :C29H27F3N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :532.56KRN383
CAS :<p>KRN383 inhibits ITD cell growth at ≤2.9 nM, erases ITD tumors in mice at 80 mg/kg dose, and may suit various treatment plans.</p>Formule :C17H17N3O4Couleur et forme :SolidMasse moléculaire :327.33YH-306
CAS :<p>YH-306 (TRV055 acetate ) is a modulator of the FAK signaling pathway that acts by suppressing colorectal tumor growth and metastasis.</p>Formule :C19H18N2O2Degré de pureté :98.06%Couleur et forme :SolidMasse moléculaire :306.36Multi-kinase-IN-2
CAS :<p>Orally active Multi-kinase-IN-2 blocks angiokinases including VEGFR, PDGFR, FGFR, and more, reducing AKT/ERK phosphorylation and promoting apoptosis.</p>Formule :C34H35N5O3Couleur et forme :SolidMasse moléculaire :561.67ER 27319 maleate
CAS :<p>Selective inhibitor of Syk kinase</p>Formule :C22H24N2O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :396.44Momelotinib Mesylate
CAS :<p>Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.</p>Formule :C24H26N6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :510.57TL02-59 dihydrochloride
CAS :<p>TL02-59 dihydrochloride is an orally active inhibitor of Src-family kinase Fgr (IC50: 0.03 nM).</p>Formule :C32H36Cl2F3N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :682.56LRRK2/NUAK1/TYK2-IN-1
CAS :<p>LRRK2/NUAK1/TYK2-IN-1 inhibits LRRK2, TYK2, NUAK1 with IC50 < 10 nM, useful in autoimmune research.</p>Formule :C20H11F3N6Couleur et forme :SolidMasse moléculaire :392.34EGFR-IN-28
CAS :<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Formule :C31H39BrN10O3SCouleur et forme :SolidMasse moléculaire :711.68AP 24149
CAS :<p>AP 24149, a potent dual inhibitor targeting Src and Abl, exhibits IC50 values of 9.1 nM for Src and 3.6 nM for Abl, respectively.</p>Formule :C23H24N5OPCouleur et forme :SolidMasse moléculaire :417.44FGFR-IN-9
<p>FGFR-IN-9: oral FGFR inhibitor, IC50: 17.1 nM (FGFR4 WT), 29.6 (FGFR3), 30.7 (V550L), 46.7 (FGFR2), 64.3 nM (FGFR1).</p>Formule :C25H28N6O3SCouleur et forme :SolidMasse moléculaire :492.59GW837016X
CAS :<p>GW837016X, also known as NEU-391, is a potent inhibitor of protozoan parasite proliferation.</p>Formule :C25H20ClFN4OSCouleur et forme :SolidMasse moléculaire :478.97TG53
CAS :<p>TG53 is a tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction inhibitor.</p>Formule :C21H22ClN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :411.88Thi-DPPY
CAS :<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Formule :C28H28ClN5O4SCouleur et forme :SolidMasse moléculaire :566.07CAY10717
CAS :<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Formule :C29H25F3N6O3Couleur et forme :SolidMasse moléculaire :562.54Peficitinib hydrobromide
CAS :<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Formule :C18H23BrN4O2Couleur et forme :SolidMasse moléculaire :407.312EGFR-IN-53
CAS :<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Formule :C14H13N3O2SCouleur et forme :SolidMasse moléculaire :287.34FGFR-IN-3
CAS :<p>FGFR-IN-3: potent, oral FGFR modulator, BBB-penetrating, neuroprotective, potential in neurodegeneration study.</p>Formule :C18H27F2N5O2Couleur et forme :SolidMasse moléculaire :383.44Derazantinib Racemate
CAS :<p>Derazantinib Racemate is an oral ATP competitive kinase inhibitor targeting FGFR1/2/3 (IC50s: 4.5/1.8/4.5 nM).</p>Formule :C29H29FN4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :468.57EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Formule :C10H6N6S2Couleur et forme :SolidMasse moléculaire :274.32EGFR-IN-40
CAS :<p>EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).</p>Formule :C23H20N6O3Couleur et forme :SolidMasse moléculaire :428.44(E/Z)-AG490
CAS :<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Formule :C17H14N2O3Couleur et forme :SolidMasse moléculaire :294.3FLT3-IN-11
CAS :<p>FLT3-IN-11, an oral FLT3 kinase inhibitor: potent, selective, IC50 - wild-type 7.22 nM, FLT3-D835Y 4.95 nM, anti-AML IC50 3.2 nM for MV4-11.</p>Formule :C20H25F3N6OCouleur et forme :SolidMasse moléculaire :422.45FLT3/CDK4-IN-1
CAS :<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Formule :C25H28F2N8Couleur et forme :SolidMasse moléculaire :478.54PD 173955-Analog1
CAS :<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Formule :C21H14Cl2N4O3Couleur et forme :SolidMasse moléculaire :441.27AhR modulator-1
CAS :<p>AhR modulator-1: orally active, selective, inhibits metastasis and prostatic VEGF, anti-estrogenic in rat uterus.</p>Formule :C13H7Cl3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :285.55FAK-IN-5
CAS :<p>FAK-IN-5 is a FAK signaling inhibitor that induces apoptosis and autophagy.</p>Formule :C29H29ClF3N3O4Couleur et forme :SolidMasse moléculaire :576.01Povorcitinib
CAS :<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Formule :C23H22F5N7OCouleur et forme :SolidMasse moléculaire :507.469JS25
CAS :<p>JS25, a selective BTK inhibitor, inactivates it with a 5.8 nM IC50, halts cancer cell growth, induces death, and aids against lymphoma.</p>Formule :C29H24N4O4SCouleur et forme :SolidMasse moléculaire :524.59(2R,5S)-Ritlecitinib
CAS :<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Formule :C15H19N5OCouleur et forme :SolidMasse moléculaire :285.34QL-X-138
CAS :<p>QL-X-138: Dual BTK/MNK inhibitor; covalent to BTK, IC50=9.4 nM; non-covalent to MNK1/2, IC50=107.4/26 nM; dengue virus 2 IC50=3.5 μM; for B-cell malignancies.</p>Formule :C25H19N5O2Degré de pureté :98.82% - 99.50%Couleur et forme :SolidMasse moléculaire :421.45TUL01101
CAS :<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Formule :C22H25F2N5O2Couleur et forme :SolidMasse moléculaire :429.46HP1328
CAS :<p>HP1328: potent FLT3/ITD inhibitor, reduces leukemia, extends survival in mice, belongs to benzoimidazole family.</p>Formule :C23H23N3O3Couleur et forme :SolidMasse moléculaire :389.45FLT3-IN-17
CAS :<p>FLT3-IN-17: FAK inhibitor, IC50 of 12 nM; blocks CYPs, FLT3 mutants; IC50 <0.5 nM for D835Y in cancer studies.</p>Formule :C23H24N6O2S2Couleur et forme :SolidMasse moléculaire :480.61c-Met-IN-11
CAS :<p>c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).</p>Formule :C30H20F2N4O3Couleur et forme :SolidMasse moléculaire :522.5LS-104
CAS :<p>LS-104 is a JAK2 inhibitor.</p>Formule :C19H16N2O3Couleur et forme :SolidMasse moléculaire :320.34BLK degrader 1
CAS :<p>BLK degrader 1 is a BLK degrader with anticancer activity for cancer research.</p>Formule :C32H25F3N6O2Degré de pureté :99.22% - 99.24%Couleur et forme :SolidMasse moléculaire :582.58VEGFR-2-IN-28
CAS :<p>VEGFR-2-IN-28 is a potent inhibitor of VEGFR-2 (IC50: 0.83 μM). VEGFR-2-IN-28 induces apoptosis and exhibits antitumor effects.</p>Formule :C26H17N7O7Couleur et forme :SolidMasse moléculaire :539.46FGFR3-IN-5
CAS :<p>FGFR3-IN-5: potent, selective FGFR3 inhibitor. IC50: 3 nM FGFR3, 44 nM FGFR2, 289 nM FGFR1. For cancer research.</p>Formule :C24H24FN7O3Couleur et forme :SolidMasse moléculaire :477.49S116836
CAS :<p>S116836 is a tyrosine kinase inhibitor.</p>Formule :C27H21F3N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :502.49FAK inhibitor 5
CAS :<p>FAK inhibitor 5 is a novel allosteric FAK inhibitor, with IC50 values in the low micromolar range.</p>Formule :C20H21N3O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :367.46PDGFRα/FLT3-ITD-IN-2
CAS :<p>PDGFRα/FLT3-ITD-IN-2 is a potent inhibitor of PDGFRα (IC50>20 μM) and FLT3 (IC50: 0.004 μM).</p>Formule :C28H41N9OCouleur et forme :SolidMasse moléculaire :519.68PD173952
CAS :<p>PD173952 is a Src kinase and Myt1 inhibitor with antitumor activity, inhibits Lyn, Abl and Csk, and induces Bcr-Abl-dependent hematopoietic cell apoptosis.</p>Formule :C24H21Cl2N5O2Degré de pureté :99.5%Couleur et forme :SolidMasse moléculaire :482.36Adhesamine
CAS :<p>Adhesamine, a dumbbell molecule, enhances cell adhesion, growth, neuron differentiation, and survival via MAPK/FAK.</p>Formule :C24H32Cl4N8O2S2Couleur et forme :SolidMasse moléculaire :670.51EGFR/HER2/TS-IN-2
CAS :<p>EGFR/HER2/TS-IN-2: Strong EGFR, HER2 & TS inhibitor; EGFR IC50=0.173μM, HER2 IC50=0.125μM, TS IC50=1.12μM; kills MDA-MB-231 cells (IC50=1.69μM).</p>Formule :C26H21N7OS2Couleur et forme :SolidMasse moléculaire :511.62BSc5371
CAS :<p>BSc5371: Irreversible FLT3 inhibitor; Kds 0.83-5.8 nM for various FLT3 mutants including wild type.</p>Formule :C24H31N5O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :485.6VEGFR-2/BRAF-IN-2
<p>VEGFR-2/BRAF-IN-2 inhibits VEGFR-2, BRAF V600E, BRAF WT (IC50: 0.111/0.089/0.071 µM); induces G1 arrest and apoptosis.</p>Formule :C26H21ClF3N5O3S2Couleur et forme :SolidMasse moléculaire :608.05MAX-40279 hydrochloride
CAS :<p>MAX-40279 HCl: potent FLT3/FGFR inhibitor; potential in AML research.</p>Formule :C22H24ClFN6OSCouleur et forme :SolidMasse moléculaire :474.98Con B-1
CAS :<p>ConB-1 is a potent and selective ALK inhibitor with low toxicity to normal cells .</p>Formule :C38H52ClN7O6SCouleur et forme :SolidMasse moléculaire :770.38PDZ1i
CAS :<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Formule :C28H26N8O4Couleur et forme :SolidMasse moléculaire :538.56BIBX 1382 Dihydrochloride
CAS :<p>BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.</p>Formule :C18H21Cl3FN7Couleur et forme :SolidMasse moléculaire :460.76BCR-ABL1-IN-1
CAS :<p>BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.</p>Formule :C18H12F3N3O2Couleur et forme :SolidMasse moléculaire :359.3EGFR/HER2/CDK9-IN-1
CAS :<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Formule :C23H21N3O3S2Couleur et forme :SolidMasse moléculaire :451.56MAX-40279
CAS :<p>MAX-40279 is a potent, dual FLT3 kinase and FGFR kinase inhibitor. MAX-40279 has potential for acute myeloid leukemia (AML) studies.</p>Formule :C22H23FN6OSCouleur et forme :SolidMasse moléculaire :438.52EGFR/HER2/TS-IN-1
CAS :<p>EGFR/HER2/TS-IN-1 inhibits EGFR (0.203 μM), HER2 (0.088 μM), TS (0.168 μM), and induces apoptosis in MCF7 cells.</p>Formule :C24H15N5O4S2Couleur et forme :SolidMasse moléculaire :501.54LDC0496
CAS :<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Formule :C32H35N5O3Couleur et forme :SolidMasse moléculaire :537.65AFG210
CAS :<p>AFG210 is a novel first-generation “type II” FLT3 inhibitor.</p>Formule :C19H14F3N3O2Couleur et forme :SolidMasse moléculaire :373.33VEGFR-2-IN-23
CAS :<p>VEGFR-2-IN-23 (11b) is a potent VEGFR-2 inhibitor with an IC50 of 0.34 nM, exhibits antitumor effects, and causes G1 cell cycle arrest.</p>Formule :C22H15N5O2Couleur et forme :SolidMasse moléculaire :381.39Lck-IN-1
CAS :<p>Lck-IN-1 is a potent inhibitor of lymphocyte protein tyrosine kinase (Lck) [1].</p>Formule :C14H15N5Couleur et forme :SolidMasse moléculaire :253.3AGL 2043
CAS :<p>AGL 2043 is a potent, reversible, ATP-competitive inhibitor of type III receptor tyrosine kinases.</p>Formule :C15H12N4SCouleur et forme :SolidMasse moléculaire :280.35α7 nAchR-JAK2-STAT3 agonist 1
CAS :<p>α7 nAchR-JAK2-STAT3 agonist 1 is a potent inhibitor of the α7 nAchR-JAK2-STAT3 pathway that acts on nitric oxide (NO) (IC50: 0.32 μM).</p>Formule :C25H30O6Couleur et forme :SolidMasse moléculaire :426.5BCR-ABL-IN-5
CAS :<p>BCR-ABL-IN-5: Bcr-Abl kinase inhibitor, IC50: Bcr-AblWT 0.014 μM, Bcr-AblT315I 0.45 μM; anti-leukemia cell growth.</p>Formule :C25H21Cl2N5O2Couleur et forme :SolidMasse moléculaire :494.37Luxeptinib
CAS :<p>Luxeptinib (CG-806) is an oral, non-covalent pan-FLT3/BTK inhibitor for acute myeloid leukemia.</p>Formule :C25H17F4N5O2Couleur et forme :SolidMasse moléculaire :495.43GDC-4379
CAS :<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Formule :C21H18ClF2N7O3Couleur et forme :SolidMasse moléculaire :489.86PHA-680626
CAS :<p>PHA-680626 is a PLK inhibitor, effective on resistant leukemia cells, with IC50: Plk1 (0.53 μM), Plk2 (0.07 μM), Plk3 (1.61 μM).</p>Formule :C23H26N6O2SCouleur et forme :SolidMasse moléculaire :450.56EGFR-IN-63
CAS :<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Formule :C20H12BrN5SCouleur et forme :SolidMasse moléculaire :434.31BTK-IN-22
CAS :<p>BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.</p>Formule :C26H26N6O2Couleur et forme :SolidMasse moléculaire :454.52pan-HER-IN-2
CAS :<p>pan-HER-IN-2 (Compound C6) is an orally active, reversible, broad-spectrum HER inhibitor that acts on EGFR (IC50: 0.72 nM), HER4 (IC50: 2.0 nM), EGFRT790M (IC50</p>Formule :C19H15BrClN5OCouleur et forme :SolidMasse moléculaire :444.71EGFR/C797S-IN-1
CAS :<p>EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.</p>Formule :C28H30N4O3Couleur et forme :SolidMasse moléculaire :470.56PDGFRα/FLT3-ITD-IN-3
CAS :<p>PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM), FLT3 (IC50: 0.004 μM) and PDGFRα/FLT3-ITD-IN-3 has the potential to be</p>Formule :C26H39N9Couleur et forme :SolidMasse moléculaire :477.65CHMFL-ABL-053
CAS :<p>CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.</p>Formule :C28H26F3N7O2Couleur et forme :SolidMasse moléculaire :549.55EGFR/HER2-IN-9
CAS :<p>EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFR</p>Formule :C25H25ClFN5O4Couleur et forme :SolidMasse moléculaire :513.95Ebselen oxide
CAS :<p>Ebselen oxide (EB-2) is a HER2 inhibitor with antibacterial and antifungal activity and has shown cytoprotective effects against HN2 in vitro.</p>Formule :C13H9NO2SeDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :290.18SMU-B
CAS :<p>SMU-B is a well-tolerated c-Met/ALK dual inhibitor.</p>Formule :C26H25Cl2FN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :515.41BTK-IN-23
CAS :<p>BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.</p>Formule :C27H28N6O2Couleur et forme :SolidMasse moléculaire :468.55EGFR/CDK2-IN-1
CAS :<p>EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application in</p>Formule :C19H12BrClO2Couleur et forme :SolidMasse moléculaire :387.65Ficonalkib
CAS :<p>Ficonalkib is a potent antineoplastic agent that inhibits the Anaplastic Lymphoma Kinase (ALK) tyrosine kinase receptor.</p>Formule :C29H39N7O3SCouleur et forme :SolidMasse moléculaire :565.73PHM16
CAS :<p>PHM16 is an ATP competitive FAK and FGFR2 inhibitor.</p>Formule :C20H22N6O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :410.43BI-1622
CAS :<p>BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.</p>Formule :C26H24N10O2Couleur et forme :SolidMasse moléculaire :508.53ProMMP-9 inhibitor-3c
CAS :<p>ProMMP-9 inhibitor-3c hinders MMP-9 homodimers, blocks proMMP-9/α4β1 integrin/CD44 binding, and detaches EGFR.</p>Formule :C18H20FN3O2SCouleur et forme :SolidMasse moléculaire :361.43EGFR-IN-57
CAS :<p>EGFR-IN-57: potent EGFR-TK blocker, IC50 0.054 μM, oral. Halts VEGFR-2, CK2α, topo IIβ, tubulin. Causes G2/M, pre-G1 arrest, cancer cell death.</p>Formule :C22H15N3O2SCouleur et forme :SolidMasse moléculaire :385.44CPL304110
CAS :<p>CPL304110: oral, selective FGFR 1-3 inhibitor; IC50 - FGFR1: 0.75nM, FGFR2: 0.5nM, FGFR3: 3.05nM.</p>Formule :C25H30N6O2Couleur et forme :SolidMasse moléculaire :446.54EGFR/HER2/CDK9-IN-3
CAS :<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Formule :C24H21N3O4S2Couleur et forme :SolidMasse moléculaire :479.57EGFR-IN-52
CAS :<p>EGFR-IN-52, a potent EGFR inhibitor, has IC50s: 0.358 μM (wild-type), 86.02 μM (L858R-TK), 432.67 μM (T790M-TK); induces cancer cell apoptosis.</p>Formule :C19H18N4O3SCouleur et forme :SolidMasse moléculaire :382.44UNC-CA359
CAS :<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Formule :C18H14ClN3O2Couleur et forme :SolidMasse moléculaire :339.78NSC 33994
CAS :<p>NSC 33994 is a selective inhibitor of JAK2 (IC50 = 60 nM). It also shows no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM.</p>Formule :C28H42N2O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :438.65JAK3/BTK-IN-6
CAS :<p>JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.</p>Formule :C21H17BF3N5O3Couleur et forme :SolidMasse moléculaire :455.2EGFR-IN-21
CAS :<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Formule :C36H44BrN10O2PCouleur et forme :SolidMasse moléculaire :759.68BCR-ABL-IN-6
CAS :<p>BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.</p>Formule :C27H22F3N5O2Couleur et forme :SolidMasse moléculaire :505.49VS 8
CAS :<p>VS 8: potent oral VEGFR-2 inhibitor, anti-angiogenic, induces cancer cell apoptosis & migration, acts on CSCs.</p>Formule :C26H20F3N3O3Couleur et forme :SolidMasse moléculaire :479.45EGFR/HER2-IN-2
CAS :<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Formule :C26H23N5O3Couleur et forme :SolidMasse moléculaire :453.49JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Formule :C31H30ClFN4O3SCouleur et forme :SolidMasse moléculaire :593.11EGFR-IN-25
CAS :<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Formule :C34H43N9O2Couleur et forme :SolidMasse moléculaire :609.76EGFR-IN-54
CAS :<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Formule :C17H14N4O4S3Couleur et forme :SolidMasse moléculaire :434.51NSC114792
CAS :<p>NSC114792 is a selective JAK3 inhibitor.</p>Formule :C26H32N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.62SUN13837
CAS :<p>SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.</p>Formule :C21H29N5O2Couleur et forme :SolidMasse moléculaire :383.49TYK2-IN-11
CAS :<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Formule :C18H17N5O3SCouleur et forme :SolidMasse moléculaire :383.42EGFR/HER2-IN-3
CAS :<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Formule :C26H23N5O3Couleur et forme :SolidMasse moléculaire :453.49FLT3-IN-18
CAS :<p>FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.</p>Formule :C26H36N8OCouleur et forme :SolidMasse moléculaire :476.62(R)-Elsubrutinib
CAS :<p>(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is used in research on immune diseases and cancer.</p>Formule :C17H19N3O2Couleur et forme :SolidMasse moléculaire :297.35EGFR-IN-69
CAS :<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Formule :C31H37Cl2N7O3SCouleur et forme :SolidMasse moléculaire :658.64VEGFR2 Kinase Inhibitor II
CAS :<p>VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.</p>Formule :C17H15BrN2OCouleur et forme :SolidMasse moléculaire :343.22

